Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis - Archive ouverte HAL Access content directly
Journal Articles JAMA Dermatology Year : 2021

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

(1) , (2) , (3) , (4) , (5) , (6, 7) , (8) , (9) , (2) , (2) , (2) , (2) , (2) , (10)
1
2
3
4
5
6
7
8
9
10

Dates and versions

hal-03829423 , version 1 (25-10-2022)

Identifiers

Cite

Andrew Blauvelt, Henrique Teixeira, Eric Simpson, Antonio Costanzo, Marjolein de Bruin-Weller, et al.. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis. JAMA Dermatology, 2021, 157 (9), pp.1047. ⟨10.1001/jamadermatol.2021.3023⟩. ⟨hal-03829423⟩
0 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More